A point-of-research decision in synovial tissue engineering: Mesenchymal stromal cells, tissue derived fibroblast or CTGF-mediated mesenchymal-to-fibroblast transition

Autor: Alexandra Damerau, Marieluise Kirchner, Philipp Mertins, Frank Buttgereit, Timo Gaber

Publikováno v: European Journal of Cell Biology, Vol 103, Iss 4, Pp 151455- (2024)

Rheumatoid arthritis (RA) and osteoarthritis (OA) are prevalent inflammatory joint diseases characterized by synovitis, cartilage, and bone destruction. Fibroblast-like synoviocytes (FLSs) of the synovial membrane are a decisive factor in arthritis,

Externí odkaz: https://doaj.org/article/8b07098b82da4b5e870f61bd8a880475

A point-of-research decision in synovial tissue engineering: Mesenchymal stromal cells, tissue derived fibroblast or CTGF-mediated mesenchymal-to-fibroblast transition

Autor: Damerau, Alexandra, Kirchner, Marieluise, Mertins, Philipp, Buttgereit, Frank, Gaber, Timo

Publikováno v: In European Journal of Cell Biology December 2024 103(4)

Human serum-derived α-synuclein auto-antibodies mediate NMDA receptor-dependent degeneration of CNS neurons

Autor: Pretty Garg, Franziska Würtz, Fabian Hobbie, Klemens Buttgereit, Abhishek Aich, Kristian Leite, Peter Rehling, Sebastian Kügler, Mathias Bähr

Publikováno v: Journal of Neuroinflammation, Vol 21, Iss 1, Pp 1-16 (2024)

Abstract Background Presence of autoantibodies against α-synuclein (α-syn AAb) in serum of the general population has been widely reported. That such peripheral factors may be involved in central nervous system pathophysiology was demonstrated by d

Externí odkaz: https://doaj.org/article/e0c5f527c41447b8b5608a7f0795d2c4

Definition, acronyms, nomenclature, and classification of angioedema (DANCE): AAAAI, ACAAI, ACARE, and APAAACI DANCE consensus

Autor: Reshef, Avner, Buttgereit, Thomas, Betschel, Stephen D., Caballero, Teresa, Farkas, Henriette, Grumach, Anete S., Hide, Michihiro, Jindal, Ankur K., Longhurst, Hilary, Peter, Jonathan, Riedl, Marc A., Zhi, Yuxiang, Aberer, Werner, Abuzakouk, Mohamed, Al Farsi, Tariq, Al Sukaiti, Nashat, Al-Ahmad, Mona, Altrichter, Sabine, Aygören-Pürsün, Emel, Baeza, Maria Luisa, Bara, Noemi Anna, Bauer, Andrea, Bernstein, Jonathan A., Boccon-Gibod, Isabelle, Bonnekoh, Hanna, Bouillet, Laurence, Brzoza, Zenon, Bygum, Anette, Calderon, Oscar, de Albuquerque Campos, Regis, Campos Romero, Freya Helena, Cancian, Mauro, Chong-Neto, Herberto Jose, Christoff, George, Cimbollek, Stefan, Cohn, Danny M., Craig, Timothy, Danilycheva, Inna, Darlenski, Razvigor, Du-Thanh, Aurélie, Ensina, Luis Felipe, Fomina, Daria, Fonacier, Luz, Fukunaga, Atsushi, Gelincik, Asli, Giavina-Bianchi, Pedro, Godse, Kiran, Gompels, Mark, Goncalo, Margarida, Gotua, Maia, Guidos-Fogelbach, Guillermo, Guilarte, Mar, Kasperska-Zajac, Alicja, Katelaris, Constance H., Kinaciyan, Tamar, Kolkhir, Pavel, Kulthanan, Kanokvalai, Kurowski, Marcin, Latysheva, Elena, Lauerma, Antti, Launay, David, Lleonart, Ramon, Lumry, William, Malbran, Alejandro, Ali, Ramzy Mohammed, Nasr, Iman, Nieto-Martinez, Sandra, Parisi, Claudio, Pawankar, Ruby, Piñero-Saavedra, Macarena, Popov, Todor A., Porebski, Grzegorz, Prieto Garcia, Alicia, Pyatilova, Polina, Rudenko, Michael, Sekerel, Bulent Enis, Serpa, Faradiba Sarquis, Sheikh, Farrukh, Siebenhaar, Frank, Soria, Angèle, Staevska, Maria, Staubach, Petra, Stobiecki, Marcin, Thomsen, Simon Francis, Triggiani, Massimo, Valerieva, Anna, Valle, Solange, Van Dinh, Nguyen, Vera Ayala, Carolina Elisa, Zalewska-Janowska, Anna, Zanichelli, Andrea, Magerl, Markus, Maurer, Marcus

Publikováno v: In The Journal of Allergy and Clinical Immunology August 2024 154(2):398-411

The real life experience goes on: update after 4 years on the first cohort treated with lanadelumab at our center

Autor: Thomas Buttgereit, Carolina Vera Ayala, Seda Aykanat, Karsten Weller, Annika Gutsche, Marcus Maurer, Markus Magerl

Publikováno v: Frontiers in Immunology, Vol 15 (2024)

IntroductionLanadelumab is a first-line long-term prophylaxis (LTP) in hereditary angioedema (HAE). Real-life data on its long-term efficacy and safety are limited. It is unknown whether patients using lanadelumab need short-term prophylaxis (STP).Ob

Externí odkaz: https://doaj.org/article/7536b60b93bf481ea32a454fc35cf1e6